Ignite Creation Date:
2024-05-06 @ 1:23 AM
Last Modification Date:
2024-10-26 @ 11:03 AM
Study NCT ID:
NCT01792193
Status:
COMPLETED
Last Update Posted:
2016-03-17
First Post:
2013-02-08
Brief Title:
Gut-derived Neuropeptides in Cerebrospinal Fluid of Patients With Parkinsons Disease and Healthy Controls
Sponsor:
Dr Marcus Unger
Organization:
Universität des Saarlandes
Study Overview
Official Title:
Quantitative Analysis of Gut-derived Neuropeptides in Cerebrospinal Fluid CSF of Patients With Parkinsons Disease and Healthy Controls
Status:
COMPLETED
Status Verified Date:
2016-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In previous work the investigators analyzed the concentration of gut-derived peptides ghrelin pancreatic polypeptide PP in serum of patients with Parkinsons disease PD The investigators have shown that the secretion pattern differs between PD patients and controls Beside ghrelin and pancreatic polypeptide other gut-derived peptides eg Glucagon-like-Peptide 1GLP-1 Amylin etc might be relevant for PD as well The rational to investigate gut-derived peptides in the neurological disorder Parkinsons disease PD is based on the following considerations
Receptors for gut-derived peptides are expressed in Central Nervous System CNS structures that are affected by the neurodegenerative process underlying Parkinsons disease
Gut-derived peptides are involved in the modulation of higher brain functions mood cognition reward-related behaviour that are frequently altered in Parkinsons disease
The secretion of gut peptides is co-regulated by the vagal nerve that is dysfunctional in Parkinsons disease
Certain gut-derived peptides ghrelin GLP-1 stimulate neurogenesis and might be able to prevent cell death in neurodegenerative disorders including Parkinsons disease
Objective
Collection of CSF and serum samples in a standardized way in order to quantitatively measure the concentration of gut-derived peptides ghrelin leptin glucose-dependent insulinotropic peptide GIP GLP-1 amylin PP peptide YY PYY and insulin Scientific questions
1 Do CSF and serum concentrations of these gut peptides differ between PD patients and controls
2 Do CSF and serum concentrations of the investigated peptides correlate with clinical and or epidemiological characteristics of the investigated subjects age gender BMI disease duration severity of motor impairments presence of non-motor symptoms co-morbidities medication etc
Receptors for gut-derived peptides are expressed in Central Nervous System CNS structures that are affected by the neurodegenerative process underlying Parkinsons disease
Gut-derived peptides are involved in the modulation of higher brain functions mood cognition reward-related behaviour that are frequently altered in Parkinsons disease
The secretion of gut peptides is co-regulated by the vagal nerve that is dysfunctional in Parkinsons disease
Certain gut-derived peptides ghrelin GLP-1 stimulate neurogenesis and might be able to prevent cell death in neurodegenerative disorders including Parkinsons disease
Objective
Collection of CSF and serum samples in a standardized way in order to quantitatively measure the concentration of gut-derived peptides ghrelin leptin glucose-dependent insulinotropic peptide GIP GLP-1 amylin PP peptide YY PYY and insulin Scientific questions
1 Do CSF and serum concentrations of these gut peptides differ between PD patients and controls
2 Do CSF and serum concentrations of the investigated peptides correlate with clinical and or epidemiological characteristics of the investigated subjects age gender BMI disease duration severity of motor impairments presence of non-motor symptoms co-morbidities medication etc
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None